COMPARISON OF LASER PHOTOCOAGULATION FOR DIABETIC RETINOPATHY USING 532-NM STANDARD LASER VERSUS MULTISPOT PATTERN SCAN LASER

Retina ◽  
2010 ◽  
Vol 30 (3) ◽  
pp. 452-458 ◽  
Author(s):  
MANISH NAGPAL ◽  
SANGITA MARLECHA ◽  
KAMAL NAGPAL
Keyword(s):  
Diabetic Retinopathy ◽  
Laser Photocoagulation ◽  
Pattern Scan Laser ◽  
Standard Laser ◽  
532 Nm

Bevacizumab-Augmented Retinal Laser Photocoagulation in Proliferative Diabetic Retinopathy: A Randomized Double-Masked Clinical Trial

2008 ◽  
Vol 18 (2) ◽  
pp. 263-269 ◽  
Author(s):  
A. Mirshahi ◽  
R. Roohipoor ◽  
A. Lashay ◽  
S.-F. Mohammadi ◽  
A. Abdoallahi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Diabetic Retinopathy ◽  
High Risk ◽  
Laser Treatment ◽  
Proliferative Diabetic Retinopathy ◽  
Laser Photocoagulation ◽  
Intravitreal Bevacizumab ◽  
Complete Regression ◽  
Standard Laser ◽  
Risk Characteristic

Purpose To evaluate the additional therapeutic effect of single intravitreal bevacizumab injection on standard laser treatment in the management of proliferative diabetic retinopathy. Methods A prospective, fellow-eye sham controlled clinical trial was conducted on 80 eyes of 40 high-risk characteristic proliferative diabetic retinopathy type II diabetics. All cases received standard laser treatment according to Early Treatment Diabetic Retinopathy Study protocol. Avastin-assigned eyes received 1.25 mg intravitreal bevacizumab (Genentech Inc., San Francisco, CA) on the first session of their laser treatments. Fluorescein angiography was performed at baseline and at weeks 6 and 16, and proliferative diabetic retinopathy regression was evaluated in a masked fashion. Results The median age was 52 years (range: 39–68) and 30% of the participants were male. All patients were followed for 16 weeks. A total of 87.5% of Avastin-injected eyes and 25% of sham group showed complete regression at week 6 of follow-up (pp<0.005). However, at week 16, PDR recurred in a sizable number of the Avastin-treated eyes, and the complete regression rate in the two groups became identical (25%; p=1.000); partial regression rates were 70% vs 65%. In the subgroup of Avastin-treated eyes, multivariate analysis identified hemoglobin A1c as the strongest predictor of proliferative diabetic retinopathy recurrence (p=0.033). Conclusions Intravitreal bevacizumab remarkably augmented the short-term response to scatter panretinal laser photocoagulation in high-risk characteristic proliferative diabetic retinopathy but the effect was short-lived, as many of the eyes showed rapid recurrence. Alternative dosing (multiple and/or periodic intravitreal Avastin injections) is recommended for further evaluation.

scholarly journals Bullous Exudative Retinal Detachment after Retinal Pattern Scan Laser Photocoagulation in Diabetic Retinopathy

2017 ◽  
Vol 8 (3) ◽  
pp. 475-481 ◽  
Author(s):  
Shohei Nishikawa ◽  
Hiroshi Kunikata ◽  
Naoko Aizawa ◽  
Toru Nakazawa
Keyword(s):  
Diabetic Retinopathy ◽  
Retinal Detachment ◽  
Laser Photocoagulation ◽  
Standard Treatment ◽  
Case Series ◽  
Exudative Retinal Detachment ◽  
Moderate Number ◽  
Key Points ◽  
Pattern Scan Laser ◽  
Retinal Photocoagulation

Laser retinal photocoagulation is the gold standard treatment for diabetic retinopathy. We describe 3 cases in which bullous exudative retinal detachment (ERD) developed after pattern scan laser photocoagulation (PASCAL) in diabetic retinopathy. ERD spontaneously resolved in all 3 cases with various visual courses. This case series highlights 2 key points: first, ERD can occur regardless of gender, age, glycemic control, or vitreous status and despite a moderate number of laser shots, even with PASCAL; second, ERD in nonvitrectomized eyes may cause irreversible visual loss, even if the ERD resolves within 1 month.

scholarly journals LASER PHOTOCOAGULATION FOR PROLIFERATIVE DIABETIC RETINOPATHY, SINGLE SPOT 532-nm vs MULTISPOT 577-nm: VERY SHORT TERM CLINICAL EFFICACY

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Diego Valera-Cornejo ◽  
Jaime Quiroz-Mendoza ◽  
Alejandro Arias-Gomez ◽  
Marlon Garcia-Roa ◽  
Paulina Ramirez-Neria ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Laser Treatment ◽  
Diode Laser ◽  
Laser Photocoagulation ◽  
Short Term ◽  
Single Spot ◽  
Significant Difference ◽  
532 Nm ◽  
Retinal Photocoagulation ◽  
Group 1

ABSTRACT This study aimed to compare clinical efficacy of retinal laser photocoagulation using a 577-nm multi-spot laser with pulses of 20 ms versus conventional 532-nm single-spot laser treatment with pulses of 100 ms, on the same patient with proliferative diabetic retinopathy (PDR) during 6-weeks follow-up. We included 46 eyes of patients treated at the retina service of the Mexican Institute of Ophthalmology, Queretaro, Mexico. Pan-retinal photocoagulation (PRP) was performed on one eye (Group 1) using multi-spot PRP with the EasyRet® 577 diode laser (Quantel Medical, Cournon d’Auvergne, France). On the other eye (Group 2), laser treatment was performed by the conventional single spot method using the Oculight SL® 532 diode laser (IRIDEX Corporation, Mountain View, CA, The USA). The primary endpoint was absence of signs in which the disease was considered active at 6 weeks and the secondary outcomes included laser parameters, best-corrected visual acuity (BCVA), central macular thickness (CMT) at baseline, and 6 weeks and results of subjective pain analysis. There was no significant difference between both treatment groups regarding age, gender, BCVA or CMT at baseline. At 6 weeks, PDR activity was similar between the groups (47.8 % versus 56.5%; p =0.55). No significant difference in CMT and BCVA was observed between the groups throughout the study period. Patient-reported pain scores were similar between the groups (5.0 versus 5.8; p = 0.30). However, total time of procedure was significantly shorter in group 1 (12.9 minutes [min] versus 22.3 min; p < 0.001). No major adverse events were identified We concluded that laser photocoagulation of the retina with the use of the multi-spot technology in patients with PDR has similar short-term efficacy to that of conventional single spot retinal photocoagulation. The multi-spot laser required less time to complete the procedure with more spots delivered to compensate its lower fluency, showing similar patient tolerance.  

scholarly journals Variability of IOP following laser photocoagulation used in the treatment of diabetic retinopathy

2017 ◽  
Vol 4 (10) ◽  
pp. 3433 ◽  
Author(s):  
Sangeeta Agarwal ◽  
Amit Kumar Patel ◽  
Ramyash Singh Yadav ◽  
Ram Kumar Jaiswal ◽  
Shweta Goel
Keyword(s):  
Diabetic Retinopathy ◽  
Intraocular Pressure ◽  
Laser Photocoagulation ◽  
Green Laser ◽  
Angle Closure ◽  
Industrialized Countries ◽  
Chi Square ◽  
Medical College ◽  
Chi Square Test ◽  
532 Nm

Background: Diabetic retinopathy (DR) is the leading cause of blindness in most industrialized countries. This study was undertaken to assess the variability of IOP following laser photocoagulation used in the treatment of diabetic retinopathy.Methods: This study was conducted at Department of Opthalmology, B.R.D. Medical College, Gorakhpur from June 2015 to December 2016. This study was intended to see the onset and duration of intraocular pressure spikes in diabetic retinopathy patients after green laser photocoagulation (532 nm) (Nidek). Forty patients were followed for next 3 months. The data was analysed by using SPSS version 15.0. Chi-square test and T test was used.Results: Out of 40 patients, 2 (5%) had background Diabetic retinopathy (DR) with maculopathy, 10 (25%) having pre-proliferative DR, 28 (70%) having proliferative DR. Out of 2 BDR patients, 1 (50%) developed immediate post laser angle closure (Schaffer's grade 1) which persisted for 3 days and another had shown no change in angle structure. Out of 10 PPDR patients, no one developed post laser angle closure (0%). Out of 28 PDR patients, 6 (21.4%) had post laser angle closure which included 4 patients who had angle closure before laser, that means around 7% patients developed angle closure in this group. Among these 2 patients, 1 developed angle closure immediately (Schaffer's grade 1) and another developed the same 1 day later and this angle closure (Schaffer's grade 1) remained for 3 days.Conclusions: Laser photocoagulation in diabetic retinopathy patients can cause increase in IOP.

The efficacy of using 532 nm and 577 nm lasers in diabetic retinopathy

2018 ◽  
pp. 20-22
Author(s):  
D.A. Goydin ◽  
◽  
S.V. Shutova ◽  
A.P. Goydin ◽  
O.L. Fabrikantov ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
532 Nm

Laser photocoagulation for diabetic retinopathy

2008 ◽  
Author(s):  
Brendan Dineen ◽  
Frank Waldron-Lynch ◽  
Fiona Harney ◽  
Sean F Dinneen ◽  
Andrew Murphy
Keyword(s):  
Diabetic Retinopathy ◽  
Laser Photocoagulation

Efficacy of Intravitreal Triamcinolone after or Concomitant with Laser Photocoagulation in Nonproliferative Diabetic Retinopathy with Macular Edema

2009 ◽  
Vol 19 (4) ◽  
pp. 630-637 ◽  
Author(s):  
Erdinc Aydin ◽  
Helin Deniz Demir ◽  
Huseyin Yardim ◽  
Unal Erkorkmaz
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Laser Photocoagulation ◽  
Control Group ◽  
Clinical Effects ◽  
Intravitreal Triamcinolone ◽  
Nonproliferative Diabetic Retinopathy ◽  
Significant Difference ◽  
Group 3 ◽  
The Mean

Purpose To investigate the clinical effects and outcomes of intravitreal injection of 4 mg of triamcinolone acetonide (IVTA) after or concomitant with macular laser photocoagulation (MP) for clinically significant macular edema (CSME). Methods Forty-nine eyes of 49 patients with nonproliferative diabetic retinopathy and CSME were randomized into three groups. The eyes in the laser group (n=17), group 1, were subjected to MP 3 weeks after IVTA; the eyes in the IVTA group (n=13), group 2, were subjected to MP, concomitant with IVTA; the eyes in the control group (n=19), group 3, underwent only IVTA application. Visual acuity (VA), fundus fluorescein angiography, and photography were performed in each group. Results In the first group, the mean VA improved from 0.17±0.09 at baseline to 0.28±0.15 (p=0.114) and in the second group, deteriorated from 0.19±0.08 at baseline to 0.14±0.08 at the sixth month (p=0.141), respectively. In Group 3, the mean VA improved from 0.16±0.08 at baseline to 0.28±0.18 (p=0.118) at the end of the follow-up. When VA was compared between the control and study groups, significant difference was detected at the sixth month (p=0.038). Conclusions MP after IVTA improved VA, rather than MP concomitant with IVTA, and only IVTA application for CSME. MP after IVTA may reduce the recurrence of CSME and needs further investigations in a longer period.

Sign in / Sign up

Export Citation Format

Share Document